Trial reportInternational journal of radiation oncology, biology, physics2026
Long-Term Outcomes After Proton Therapy Versus Intensity Modulated Photon Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer: Post Hoc Analysis of a Prospective Randomized Trial.
Trial report in International journal of radiation oncology, biology, physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
Abstract
purposeTo report long-term toxicity and disease outcomes from a randomized trial comparing passive scattering proton therapy (PSPT) and intensity modulated photon radiation therapy (IMRT), both with concurrent chemotherapy, for non-small cell lung cancer. METHODS AND MATERIALS: One hundred forty-nine patients with locally advanced non-small cell lung cancer were randomly assigned to IMRT or PSPT; 147 completed the assigned treatment. Local failure, radiation pneumonitis (RP), major adverse cardiac events (MACEs), long-term esophageal toxicity, and survival were estimated and compared between IMRT and PSPT. Risk factors for each endpoint were analyzed using Cox proportional hazards regression or competing-risks regression.
resultsThe median follow-up time was 28.5 months (29.7 months IMRT, 26.2 months PSPT); 7 patients were lost to follow-up. Grade ≥3 RP was experienced by 10 patients in the IMRT group (10.9%) and 6 in the PSPT group (10.5%; P = .98); 2 patients treated with IMRT and no patients treated with PSPT had grade 5 RP. Pre-existing pulmonary disease and mean lung dose were found to be associated with grade ≥3 RP. Esophageal toxicity rates did not differ between groups and consisted of 7 grade 3 strictures and 1 secondary cancer. Of the 10 definitely/possibly radiation-related MACEs, 1 was in PSPT, and 9 were in IMRT; doses to coronary arteries may have been associated with MACE. No differences were found in local failure or progression-free survival. Tumor volume and radiation dose influenced survival outcomes.
conclusionsWhen both IMRT and PSPT plans met dose-volume constraints for the lung, no differences were found in lung toxicity or local failure after IMRT versus PSPT, consistent with our original findings. PSPT led to fewer cases of radiation-related MACE, presumably from reduced radiation dose to the coronary arteries. Survival outcomes were comparable to those of Radiation Therapy Oncology Group 0617, a phase 3 trial that included only patients with stage IIB to IIIA disease and good performance status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.